SLS - SELLAS to Host Corporate Update Webinar on January 3 2024 at 8:30 am ET | Benzinga
NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a corporate update webinar on Wednesday, January 3, 2024, at 8:30 a.m. Eastern Time.
Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will discuss the Company's achievements in 2023 and provide an outlook for 2024. Dr. Stergiou will be joined by two key opinion leaders and principal investigators who will discuss the Phase 3 registrational REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia and the clinical program for SLS009, the Company's CDK9 inhibitor:
- Dr. Panagiotis Tsirigotis, Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
- Dr. Tapan Kadia, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas
To access the webinar, please use the following information:
| Date: |
| Wednesday, January 3, 2024 |